Report: Drug-Eluting Balloon Revenue to More than Double by 2019
•Global DEB market revenue to climb by 16% in seven years
•DEB’s ability to target challenging patient populations will help ‘expand the market over the coming years,’ says analyst
Drug-Eluting Balloon Revenue to More than Double by 2019, Following US and Japanese Debut
LONDON, UK (GlobalData), 23 October 2013 - The global sales of drug-eluting balloons (DEBs) across the 10 major markets (10MM) are expected to witness a significant increase over the coming years, from $164m in 2012 to $477m in 2019, at a Compound Annual Growth Rate (CAGR) of 16%, following the product’s launch in the US and Japanese markets, according to a new report from research and consulting firm GlobalData.
The company’s latest report* states that by 2019, the US, UK, France, Germany, Italy, Spain and Japan will account for approximately 70% of the DEB market for coronary artery disease (CAD) and peripheral artery disease (PAD) in the lower extremity. Among the 10 countries covered in the report, the US is forecast to boast the largest share in the DEB market, with 26% by 2019.
The demand for effective therapies targeting indications such as in-stent restenosis and complex lesions, and reducing complications associated with drug-eluting stenting (DES), will be primary drivers behind the market growth. Downstream cost-saving measures are also expected to contribute, along with an increasing prevalence in CAD and PAD.
Priya Madhavan, GlobalData’s Analyst covering Cardiovascular Devices, says: “The DEB market is a dynamic one, where the technology has the potential to be an alternative therapy option for patients suffering from CAD and PAD. DEB can be utilized for select coronary and peripheral indications, including for patients who are not eligible for DES, and we expect this to expand the market over the coming years by targeting challenging patient populations.”
Despite the anticipated level of DEB market growth by 2019, GlobalData also expects a number of barriers to prevent any further increase in revenue.
These include a lack of clinical data, as well as numerous reimbursement issues. The fact that DEBs are not reimbursed in the public healthcare system in countries such as France, Brazil and India means that adoption of the technology among these countries is slow. The high selling price and regulatory challenges surrounding DEBs are also proving a hindrance to their take-up.
Madhavan continues: “Physicians and regulatory authorities want to see long-term clinical data that demonstrate the superiority of DEB angioplasty when compared with stenting.
“Comparative studies looking at the efficacy of different DEB products are essential for developing therapies that improve patient outcomes, and robust clinical data will assist DEBs in receiving approval from the US Food and Drug Association (FDA) and Japanese Pharmaceuticals Medical Devices Agency (PMDA) in order to launch within these markets.”
*MediPoint: Drug-Eluting Balloons – Global Analysis and Market Forecasts
-NOTES TO EDITORS-
This report provides information and analysis on the global drug-eluting balloons (DEB) market, including in-depth insight into the use of DEB for coronary and peripheral applications in the lower extremity.
This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GlobalData’s team of industry experts.
For guidelines on how to cite GlobalData, please see: http://www.globaldata.com/QuotingGlobalData.aspx
GlobalData is a leading global research and consulting firm offering advanced analytics to help clients make better, more informed decisions every day. Our research and analysis is based on the expert knowledge of over 700 qualified business analysts and 25,000 interviews conducted with industry insiders every year, enabling us to offer the most relevant, reliable and actionable strategic business intelligence available for a wide range of industries.
For more information, please contact our Press Office on +44 (0)1204 543 537 or at firstname.lastname@example.org
Posted: October 2013